Catalyst Brief

← Calendar

Readoutin 75d

Janssen Research & Development, LLC — Icotrokinra

Phase 3 primary completion: A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis.

Date
Feb 2027
Type
Readout
Indication
Arthritis, Psoriatic

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Janssen Research & Development, LLC

  1. Feb2027
  2. Dec2026
  3. Dec2026